Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC001 in Advanced Epithelial Solid Tumors
NCT07644403Phase 2Enrolling by invitation
- Sponsor
- Immunofoco
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous CAR-T cell injection targeting EpCAM in Epithelial neoplasm, sponsored by Immunofoco. Primary endpoints: Dose Limiting Toxicity at 28 days, Recommended Phase II Dose and 1 more. Started Mar 2026; status: enrolling by invitation.
02
Drugs
autologous CAR-T cell injection targeting EpCAM
03
Conditions
Epithelial neoplasm
Beyond the preview
Go deeper on NCT07644403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644403.